Abstract
Drug-eluting stents (DES) have revolutionized the treatment of coronary artery blockage by tremendously reducing the rate of in-stent restenosis and the necessity of repeat revascularization compared to bare-metal stents. They are also gaining increasing importance in other medical fields such as the treatment of certain localized tumors and in glaucoma therapy. DES generally contain most potent drugs, e.g. immunosuppressants or cytostatics, which are supposed to be released in a well controlled manner over time spans which are chosen according to disease progression. Typically, this means that fairly small amounts of drug are released over long periods of time. Therefore, quantification of in vivo plasma levels is often not feasible. Due to this limitation and the fact that tissue levels cannot be determined in humans, in vitro dissolution testing is one of the most powerful tools to gain insight into the release behaviour of DES. This article focuses on the methods for in vitro dissolution testing of DES which are available up to date and highlights the specific characteristics of drug release from stents arising from the composition and the in vivo localization of the dosage form.
Keywords: Biorelevant dissolution, drug-eluting stent, flow-through cell, in vitro dissolution, reciprocating holder, vesselsimulating flow-through cell
Current Pharmaceutical Biotechnology
Title:In Vitro Dissolution Testing of Drug-Eluting Stents
Volume: 14 Issue: 1
Author(s): Anne Seidlitz, Stefan Nagel, Beatrice Semmling, Katrin Sternberg, Heyo K. Kroemer and Werner Weitschies
Affiliation:
Keywords: Biorelevant dissolution, drug-eluting stent, flow-through cell, in vitro dissolution, reciprocating holder, vesselsimulating flow-through cell
Abstract: Drug-eluting stents (DES) have revolutionized the treatment of coronary artery blockage by tremendously reducing the rate of in-stent restenosis and the necessity of repeat revascularization compared to bare-metal stents. They are also gaining increasing importance in other medical fields such as the treatment of certain localized tumors and in glaucoma therapy. DES generally contain most potent drugs, e.g. immunosuppressants or cytostatics, which are supposed to be released in a well controlled manner over time spans which are chosen according to disease progression. Typically, this means that fairly small amounts of drug are released over long periods of time. Therefore, quantification of in vivo plasma levels is often not feasible. Due to this limitation and the fact that tissue levels cannot be determined in humans, in vitro dissolution testing is one of the most powerful tools to gain insight into the release behaviour of DES. This article focuses on the methods for in vitro dissolution testing of DES which are available up to date and highlights the specific characteristics of drug release from stents arising from the composition and the in vivo localization of the dosage form.
Export Options
About this article
Cite this article as:
Seidlitz Anne, Nagel Stefan, Semmling Beatrice, Sternberg Katrin, K. Kroemer Heyo and Weitschies Werner, In Vitro Dissolution Testing of Drug-Eluting Stents, Current Pharmaceutical Biotechnology 2013; 14 (1) . https://dx.doi.org/10.2174/1389201011314010010
DOI https://dx.doi.org/10.2174/1389201011314010010 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Statins Therapy is Associated with Increased Populations of Early Endothelial Progenitor (CD133+/VEGFR2+) and Endothelial (CD34-/CD133- /VEGFR2+) Cells in Patients with Acute Ischemic Stroke
Current Neurovascular Research Computational Methods for the Identification and Optimisation of High Quality Leads
Combinatorial Chemistry & High Throughput Screening Optimal Time for Pharmacological Treatment of Abdominal Aortic Aneurysm
Current Drug Targets Identification of Novel Pancreatic Lipase Inhibitors Using <i>In Silico</i> Studies
Endocrine, Metabolic & Immune Disorders - Drug Targets Nailfold Capillaroscopy of Fingers and Toes - Variations of Normal
Current Rheumatology Reviews From the Editors Perspective: Rational Approaches for Radical Entities
Current Neurovascular Research Leukocyte-mediated Tissue Injury in Ischemic Stroke
Current Medicinal Chemistry Sudden Cardiac Death in a Young HIV-Positive Man on Effective Antiretroviral Therapy
Current HIV Research Cerebrovascular Amyloidosis and Dementia
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Syncope in a Child with Pulmonary Hypertension and Positive Gene Tests for Hereditary Hemorrhagic Telangiectasia and Long QT Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Sulfonyl Group-Containing Compounds in the Design of Potential Drugs for the Treatment of Diabetes and Its Complications
Current Medicinal Chemistry Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice
Cardiovascular & Hematological Disorders-Drug Targets The Utility of Semi-Automating Multiplexed Assays for ADME/Tox Applications
Combinatorial Chemistry & High Throughput Screening Pre-Emptive Conditioning of the Ischemic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Neuregulin1 as Novel Therapy for Heart Failure
Current Pharmaceutical Design Role of Platelet Function Testing in Clinical Practice: Current Concepts and Future Perspectives
Current Drug Targets The FlexX Database Docking Environment - Rational Extraction of Receptor Based Pharmacophores
Current Drug Discovery Technologies Interleukin 2 in Cancer Therapy
Current Medicinal Chemistry Editorial (Thematic Issue: The Coronary Collateral Circulation – Past, Present and Future)
Current Cardiology Reviews Atorvastatin and Diabetic Vascular Complications
Current Pharmaceutical Design